A senostatic effect of Metformin was also reported, showing its ability to modulate the profile of the senescence-associated secretory phenotype elicited by LY2835219, a CDK4/6 inhibitor in HNSCC, by inhibiting the mTOR and STAT3 pathways. This evidence concerns the gene STAT3 and head and neck squamous cell carcinoma.